1％卢立康唑乳膏治疗足癣的临床疗效观察

摘要

目的 评价1％卢立康唑乳膏治疗足癣的疗效和安全性.方法 将120例患者随机分为4组,包括实验组卢立康唑2周组、卢立康唑4周组及对照组萘替芬酮康唑2周组、萘替芬酮康唑4周组.在用药结束时及停药后2周评价临床和真菌学疗效.结果 卢立康唑2周组停药时,临床有效率为67.86％,对照组为70.37％ (P＞0.05).真菌清除率为46.43％,对照组为51.85％ (P＞0.05);停药后2周,卢立康唑2周组临床有效率为85.71％,对照组为85.19％ (P＞0.05).真菌清除率为82.14％,对照组为81.48％ (P＞0.05).卢立康唑4周组停药时,临床有效率为88.89％,对照组为88.89％ (P＞0.05).真菌清除率为85.19％,对照组为88.89％ (P＞0.05);停药后2周,卢立康唑4周组临床有效率为92.59％,对照组为88.89％ (P＞0.05).真菌清除率为88.89％,对照组为88.89％ (P＞0.05);试验组和对照组药物不良反应均表现为局部刺激,发生率均为3.33％.结论 1％卢立康唑乳膏治疗足癣的疗效及安全性与萘替芬酮康唑乳膏相似.1％卢立康唑乳膏外用治疗足癣安全有效,每日1次治疗2周与治疗4周的疗效相当.%Objective To evaluate the efficacy and safety of luliconazole 1％ cream in the treatment of tinea pedis.Methods One hundred and twenty patients positive for fungal elements on direct microscopy were equally and randomly divided into 4 groups:the trial groups applying luliconazole 1％ cream for 2 weeks or 4 weeks and the control groups applying naftifine ketoconazole 2 weeks or 4 weeks.Efficacy was assessed in terms of mycological clearance and clinical response rates on week 2,4 and 6 after initiation of treatment.Results In 2-week regimen,the clinical response rates at weeks 2 were 67.86％ in trial group and 70.37％ in control group (P ＞ 0.05);The mycological clearance rates were 46.43 ％ in trial group and 51.85 ％ in control group (P ＞0.05).They were 85.71％ vs.85.19％ and 82.14％ vs.81.48％ respectively at weeks 4 (2 weeks after the end of treatment)(P＞0.05).In 4-week regimen,the clinical response rates were 88.89％ vs.88.89％ and mycological clearance rates were 85.19％ vs.88.89％ at weeks 4.They were 92.59％ vs.88.89 ％ and 88.89 ％ vs.88.89％ respectively on 2 weeks after the end of treatment (P＞0.05).Treatment-related adverse events consisted of local irritation occurred in 3.33％ of patients both in the trial group and control group.Conclusion The efficacy and safety of 1 ％ luliconazole cream in the treatment of tinea pedis are similar to that of naftifine ketoconazole cream.This study suggests that 1％ luliconazole cream was effective and safe in the treatment of tinea pedis,with the efficacy of 2-week once-daily regimen equivalent to that of 4-week once-daily regimen.